Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis
Authors:
Abstract
Background:Mometasone furoate nasal spray (MFNS, NASONEX®), is a new synthetic corticosteroid with considerable efficacy in the treatment of seasonal and perennial rhinitis and less than 0.1% systemic absorption. This study was designed to evaluate the time of onset of action of MFNS. The subjects were evaluated over the course of 2 weeks during the spring allergy season.Methods:The effects of MFNS 200 μg given once daily for 2 weeks were evaluated in a randomized, multicenter, double‐blind, placebo‐controlled study in 201 patients with seasonal allergic rhinitis. Clinically significant onset of action was assessed prospectively by special patient diary cards kept during the first 3 days of treatment.Results:By 12 h after initial dosage (the earliest evaluation), 28% of patients in the MFNS group experienced clinically significant relief, compared with 13% of those given placebo (P=0.01). Median time to at least moderate symptom relief in patients who received MFNS was 35.9 h, compared with more than 72 h in patients given placebo (PPPConclusions:MFNS provided rapid onset of clinically significant symptom relief in patients with seasonal allergic rhinitis.Keywords
This publication has 12 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitisJournal of Allergy and Clinical Immunology, 1996
- 423 Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cellsJournal of Allergy and Clinical Immunology, 1996
- Interactions of glucocorticoids and beta 2-agonistsEuropean Respiratory Journal, 1996
- 1004 Once daily mometasone furoate aqueous nasal spray in seasonal allergic rhinitis: An active and placebo-controlled studyJournal of Allergy and Clinical Immunology, 1996
- 64 Once daily mometasone furoate aqueous nasal spray is as active as twice daily beclomethasone dipropionate for perennial allergic rhinitisJournal of Allergy and Clinical Immunology, 1996
- Triamcinolone acetonide aqueous nasal spray for the treatment of patients with perennial allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled studyClinical Therapeutics, 1995
- Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: A placebo-controlled, double-blind studyClinical Therapeutics, 1995
- Effect of Topical Corticosteroids on the Recovery of Histamine Releasing Factors in Nasal Washings of Patients with Allergic Rhinitis: A Double-blind, Randomized, Placebo-controlled StudyAmerican Review of Respiratory Disease, 1992
- Cytokine Inhibition by A Novel Steroid, Mometasone FuroateImmunopharmacology and Immunotoxicology, 1991
- New directions and dimensions in the treatment of allergic rhinitisJournal of Allergy and Clinical Immunology, 1988